2005
DOI: 10.2217/17455057.1.3.323
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: Gemcitabine and paclitaxel are active drugs in the treatment of patients with metastatic breast cancer which seem to have synergistic anticancer activity. Seven Phase II trials of gemcitabine/paclitaxel and one Phase III trial have been published. Two dosing or admistration schedules have been preferred in the clinical development of the combinations: gemcitabine on days 1 and 8 plus paclitaxel on day 1 or 8, every 3 weeks or gemcitabine plus paclitaxel on day 1, every 2 weeks. In first-line Phase II trials, u… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2013
2013
2019
2019

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 8 publications
(3 citation statements)
references
References 33 publications
(44 reference statements)
0
3
0
Order By: Relevance
“…Furthermore, meta-analysis demonstrated that combination therapy statistically improved OS, ORR and PFS in patients with HER2-negative ABC compared to sequential single agent therapy [24]. It has also been reported that the combination treatment of paclitaxel and gemcitabine resulted in a survival advantage in patients with ABC compared to paclitaxel alone [26]. Moreover, Park et al reported that the efficacy of the combination treatment of eribulin and gemcitabine resulted in more favourable toxicity profiles compared to paclitaxel and gemcitabine [27].…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, meta-analysis demonstrated that combination therapy statistically improved OS, ORR and PFS in patients with HER2-negative ABC compared to sequential single agent therapy [24]. It has also been reported that the combination treatment of paclitaxel and gemcitabine resulted in a survival advantage in patients with ABC compared to paclitaxel alone [26]. Moreover, Park et al reported that the efficacy of the combination treatment of eribulin and gemcitabine resulted in more favourable toxicity profiles compared to paclitaxel and gemcitabine [27].…”
Section: Discussionmentioning
confidence: 99%
“…Such combinations have commonly been administered for the therapeutic management of neoplastic conditions affecting the breast [25-28,29] pancrease [33] lung [31] in addition to lymphoproliferative disorders [34]. Clinical trials have been conducted to evaluate the efficacy of gemcitabine in combination with vinca alkaloid (2010: sarcomas) and Brentuximab Vedotin (2011: anaplastic large cell lymphoma and Hodgkin's Lymphoma).…”
Section: Introductionmentioning
confidence: 99%
“…Gemcitabine in clinical scenarios is frequently administered in combination with tubulin/microtubule inhibitor chemotherapeutics including the vinca alkaloids [ 29 - 32 ], taxanes [ 30 , 33 , 34 ], podophyllotoxins/etoposides [ 35 - 37 ], and monomethyl auristatin E (MMAE) [ 38 ]. Such combinations have commonly been administered for the therapeutic management of neoplastic conditions affecting the breast [ 29 - 33 ] pancrease [ 37 ] lung [ 36 ], in addition to lymphoproliferative disorders [ 38 ]. Clinical trials have been conducted to evaluate the efficacy of gemcitabine in combination with vinca alkaloid (2010: sarcomas) and Brentuximab Vedotin (2011: anaplastic large cell lymphoma, Hodgkin’s Lymphoma).…”
Section: Introductionmentioning
confidence: 99%